SCHEMBL17849288

SCHEMBL17849288

Cc1ccc2cc(-c3cnc4ccc(Nc5ccc(C)c(C)c5)nn34)sc2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.43
PIK3R1 P27986 1/20 0.43
KCNH2 Q12809 5/20 0.43
MKNK1 Q9BUB5 4/20 0.42
DYRK3 O43781 2/20 0.42
CCNT1 O60563 2/20 0.42
CCNA2 P20248 2/20 0.42
CDK2 P24941 2/20 0.42
CDK9 P50750 2/20 0.42
CDK5 Q00535 2/20 0.42
DYRK1A Q13627 2/20 0.42
CDK5R1 Q15078 2/20 0.42
DYRK2 Q92630 2/20 0.42
DYRK1B Q9Y463 2/20 0.42
FYN P06241 8/20 0.38
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
NOTUM Q6P988 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16016831 0.92 PIK3CD (0.43) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL17849313 0.91 KCNH2 (0.45) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL16016966 0.89 PIK3CD (0.55) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL16016828 0.89 FYN (0.45) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL17849264 0.87 MKNK1 (0.49) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL17849266 0.85 MKNK1 (0.49) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL16016920 0.85 FYN (0.43) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL16017047 0.85 FYN (0.43) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL17849253 0.84 MKNK1 (0.43) PIK3CDPIK3R1KCNH2MKNK1DYRK3
SCHEMBL16016821 0.82 PIK3CD (0.56) PIK3CDPIK3R1KCNH2MKNK1DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS Califia Bio, Inc. 2016-08-11 US disclosed
US-9370515-B2 Mixed lineage kinase inhibitors and method of treatments Califia Bio, Inc. (US) 2016-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228437-A1 MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS MAP3K2, MAP3K1, MAP3K20 PIK3CD 316/4885PIK3R1 436/4885KCNH2 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.